{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:18:15Z","timestamp":1790803095384,"version":"4.1.0"},"reference-count":75,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:title>This Clinical Report was retired June 2025.<\/jats:title>\n               <jats:p>Appropriate prescribing practices for fluoroquinolones, as well as all antimicrobial agents, are essential as evolving resistance patterns are considered, additional treatment indications are identified, and the toxicity profile of fluoroquinolones in children has become better defined. Earlier recommendations for systemic therapy remain; expanded uses of fluoroquinolones for the treatment of certain infections are outlined in this report. Prescribing clinicians should be aware of specific adverse reactions associated with fluoroquinolones, and their use in children should continue to be limited to the treatment of infections for which no safe and effective alternative exists or in situations in which oral fluoroquinolone treatment represents a reasonable alternative to parenteral antimicrobial therapy.<\/jats:p>","DOI":"10.1542\/peds.2016-2706","type":"journal-article","created":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T05:07:26Z","timestamp":1477890446000},"source":"Crossref","is-referenced-by-count":158,"title":["The Use of Systemic and Topical Fluoroquinolones"],"prefix":"10.1542","volume":"138","author":[{"given":"Mary Anne","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon E.","family":"Schutze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"COMMITTEE ON INFECTIOUS DISEASES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Byington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne A.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Dele","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Lynfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flor M.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Nolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christine","family":"Nyquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobeen H.","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Q.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theoklis E.","family":"Zaoutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2016,11,1]]},"reference":[{"issue":"4","key":"2025082815264171600_B1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2131\/jts.3.357","article-title":"Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals.","volume":"3","author":"Tatsumi","year":"1978","journal-title":"J Toxicol Sci"},{"issue":"1","key":"2025082815264171600_B2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0041-008X(79)90020-6","article-title":"Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids.","volume":"51","author":"Gough","year":"1979","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"2025082815264171600_B3","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1542\/peds.2006-1722","article-title":"The use of systemic fluoroquinolones.","volume":"118","author":"Committee on Infectious Diseases","year":"2006","journal-title":"Pediatrics"},{"issue":"4","key":"2025082815264171600_B4","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2011-1496","article-title":"The use of systemic and topical fluoroquinolones.","volume":"128","author":"Bradley","year":"2011","journal-title":"Pediatrics"},{"key":"2025082815264171600_B5","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1016\/0002-9343(91)90308-K","article-title":"Quinolone toxicity: methods of assessment.","volume":"91","author":"Patterson","year":"1991","journal-title":"Am J Med"},{"key":"2025082815264171600_B6","article-title":"Fluoroquinolone-induced lesions in the epiphyseal growth plates of immature rats.","volume-title":"40","author":"Riecke"},{"issue":"3","key":"2025082815264171600_B7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijantimicag.2008.08.004","article-title":"Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data.","volume":"33","author":"Sendzik","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2025082815264171600_B8","unstructured":"US Food and Drug Administration, Division of Special Pathogen and Immunologic Drug Products\n          . Summary of clinical review of studies submitted in a response to a pediatric written request: ciprofloxacin. Available at: www.fda.gov\/downloads\/drugs\/developmentapprovalprocess\/developmentresources\/ucm447421.pdf. Accessed January 13, 2016"},{"issue":"7","key":"2025082815264171600_B9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00204-004-0551-6","article-title":"Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period.","volume":"78","author":"von Keutz","year":"2004","journal-title":"Arch Toxicol"},{"key":"2025082815264171600_B10","unstructured":"US Food and Drug Administration, Division of Anti-Infective Drug Products\n          . Review and evaluation of pharmacology and toxicology data: HFD-520. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/nda\/96\/020634-3.pdf. Accessed June 30, 2010"},{"issue":"2","key":"2025082815264171600_B11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/BPO.0b013e3181982c4f","article-title":"The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model.","volume":"29","author":"Sansone","year":"2009","journal-title":"J Pediatr Orthop"},{"issue":"9","key":"2025082815264171600_B12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/adc.2010.208843","article-title":"Ciprofloxacin safety in paediatrics: a systematic review.","volume":"96","author":"Adefurin","year":"2011","journal-title":"Arch Dis Child"},{"issue":"10","key":"2025082815264171600_B13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/INF.0b013e3180cbd382","article-title":"Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders.","volume":"26","author":"Noel","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"2025082815264171600_B14","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2013-3636","article-title":"Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin.","volume":"134","author":"Bradley","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"2025082815264171600_B15","first-page":"516","article-title":"Fluoroquinolone induced tendinopathy: report of 6 cases.","volume":"23","author":"Zabraniecki","year":"1996","journal-title":"J Rheumatol"},{"issue":"10","key":"2025082815264171600_B16","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/INF.0b013e3180cbd2c7","article-title":"Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.","volume":"26","author":"Bradley","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"2025082815264171600_B17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/INF.0b013e318168d2cb","article-title":"A randomized comparative study of levofloxacin versus amoxicillin\/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media.","volume":"27","author":"Noel","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"2025082815264171600_B18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1128\/9781555817817","article-title":"Mechanisms of quinolone resistance","volume-title":"Quinolone Antimicrobial Agents","author":"Hooper","year":"2003","edition":"3rd ed."},{"issue":"8","key":"2025082815264171600_B19","doi-asserted-by":"crossref","first-page":"e42919","DOI":"10.1371\/journal.pone.0042919","article-title":"The co-selection of fluoroquinolone resistance genes in the gut flora of Vietnamese children.","volume":"7","author":"Vien","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"2025082815264171600_B20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1128\/AAC.01068-07","article-title":"Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacin.","volume":"52","author":"Davies","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2025082815264171600_B21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1469-0691.2007.01681.x","article-title":"Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.","volume":"13","author":"Mesaros","year":"2007","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"2025082815264171600_B22","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1086\/592250","article-title":"Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis.","volume":"47","author":"Talan","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2025082815264171600_B23","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.amjmed.2008.04.039","article-title":"Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates.","volume":"121","author":"Johnson","year":"2008","journal-title":"Am J Med"},{"key":"2025082815264171600_B24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2334-8-4","article-title":"Increased fluoroquinolone resistance with time in Escherichia coli from &gt;17,000 patients at a large county hospital as a function of culture site, age, sex, and location.","volume":"8","author":"Boyd","year":"2008","journal-title":"BMC Infect Dis"},{"issue":"10","key":"2025082815264171600_B25","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1128\/AAC.00548-06","article-title":"Ciprofloxacin-resistant gram-negative bacilli in the fecal microflora of children.","volume":"50","author":"Qin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2025082815264171600_B26","doi-asserted-by":"crossref","first-page":"i31","DOI":"10.1093\/jac\/dkt024","article-title":"Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals.","volume":"68","author":"Adam","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2025082815264171600_B27","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/INF.0000000000000714","article-title":"Increased prevalence and resistance of important pathogens recovered from respiratory specimens of cystic fibrosis patients during a decade.","volume":"34","author":"Raidt","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"2025082815264171600_B28","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1097\/INF.0000000000000238","article-title":"The quest for the best metric of antibiotic use and its correlation with the emergence of fluoroquinolone resistance in children.","volume":"33","author":"Rose","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"2025082815264171600_B29","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1086\/673974","article-title":"Pediatric antimicrobial susceptibility trends across the United States.","volume":"34","author":"Tamma","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"2025082815264171600_B30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1542\/peds.2012-2992","article-title":"Clostridium difficile infection in infants and children.","volume":"131","author":"Schutze","year":"2013","journal-title":"Pediatrics"},{"issue":"9","key":"2025082815264171600_B31","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/jac\/dkt129","article-title":"Community-associated Clostridium difficile infection and antibiotics: a meta-analysis.","volume":"68","author":"Deshpande","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2025082815264171600_B32","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jac\/dkt477","article-title":"Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis.","volume":"69","author":"Slimings","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2025082815264171600_B33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000334441","article-title":"QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.","volume":"120","author":"Briasoulis","year":"2011","journal-title":"Cardiology"},{"issue":"1","key":"2025082815264171600_B34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1755-5922.12054","article-title":"Antibiotic-induced cardiac arrhythmias.","volume":"32","author":"Abo-Salem","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"2025082815264171600_B35","first-page":"331","article-title":"Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration.","volume":"4","author":"Torkildsen","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"2025082815264171600_B36","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/archopht.123.9.1282","article-title":"Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.","volume":"123","author":"Wagner","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"2025082815264171600_B37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11534380-000000000-00000","article-title":"Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.","volume":"12","author":"Comstock","year":"2010","journal-title":"Paediatr Drugs"},{"issue":"1","key":"2025082815264171600_B38","first-page":"CD004740","article-title":"Interventions for acute otitis externa.","author":"Kaushik","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2025082815264171600_B39","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.ijporl.2008.04.015","article-title":"Tube associated otorrhea in children with recurrent acute otitis media: results of a prospective randomized study on bacteriology and topical treatment with or without systemic antibiotics.","volume":"72","author":"Granath","year":"2008","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"4","key":"2025082815264171600_B40","first-page":"S24","article-title":"Systematic review of topical antimicrobial therapy for acute otitis externa.","volume":"134","author":"Rosenfeld","year":"2006","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"2025082815264171600_B41","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1177\/0194599813514365","article-title":"Clinical practice guideline: acute otitis externa.","volume":"150","author":"Rosenfeld","year":"2014","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"10","key":"2025082815264171600_B42","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1185\/03007995.2011.616192","article-title":"A meta-analysis of the efficacy of quinolone containing otics in comparison to antibiotic-steroid combination drugs in the local treatment of otitis externa.","volume":"27","author":"M\u00f6sges","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"2025082815264171600_B43","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1185\/030079906X121057","article-title":"Once-daily ofloxacin otic solution versus neomycin sulfate\/polymyxin B sulfate\/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa.","volume":"22","author":"Schwartz","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"2025082815264171600_B44","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1093\/cid\/cir531","article-title":"The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.","volume":"53","author":"Bradley","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2025082815264171600_B45","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2012-3488","article-title":"The diagnosis and management of acute otitis media","volume":"131","author":"Lieberthal","year":"2013","journal-title":"Pediatrics"},{"issue":"1","key":"2025082815264171600_B46","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2013-1071","article-title":"Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years.","volume":"132","author":"Wald","year":"2013","journal-title":"Pediatrics"},{"issue":"2","key":"2025082815264171600_B47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/0091270004271944","article-title":"Levofloxacin pharmacokinetics in children.","volume":"45","author":"Chien","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"2025082815264171600_B48","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/01.inf.0000246828.13834.f9","article-title":"An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media.","volume":"25","author":"Arguedas","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2025082815264171600_B49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/426817","article-title":"The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.","volume":"40","author":"Richter","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2025082815264171600_B50","unstructured":"Factive (gemifloxacin mesylate) [package insert]. Oscient Pharmaceuticals. 2008. Available at: http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=8345. Accessed July 6, 2015"},{"key":"2025082815264171600_B51","unstructured":"Avelox (moxifloxacin hydrochloride) [package insert]. Schering Plough Corporation. 2015. Available at: http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=56b4f979-bf20-4908-9d7c-5536221d77f8. Accessed July 6, 2015"},{"key":"2025082815264171600_B52","unstructured":"Levaquin (levofloxacin) [package insert]. Major Pharmaceuticals. 2013. Available at: http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=449ddc89-6dff-4e3e-a480-66b68389c73d. Accessed July 6, 2015"},{"key":"2025082815264171600_B53","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2025082815264171600_B54","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMoa012122","article-title":"Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.","volume":"346","author":"Davidson","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"2025082815264171600_B55","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1086\/499046","article-title":"The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations.","volume":"42","author":"Drusano","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2025082815264171600_B56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1345\/aph.18146","article-title":"Clinical use of fluoroquinolones in children.","volume":"34","author":"Alghasham","year":"2000","journal-title":"Ann Pharmacother"},{"issue":"8","key":"2025082815264171600_B57","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3855\/jidc.3817","article-title":"A three-year review of antimicrobial resistance of Salmonella enterica serovars Typhi and Paratyphi A in Pakistan.","volume":"8","author":"Qamar","year":"2014","journal-title":"J Infect Dev Ctries"},{"issue":"4","key":"2025082815264171600_B58","doi-asserted-by":"crossref","first-page":"e0003619","DOI":"10.1371\/journal.pntd.0003619","article-title":"Typhoid fever in young children in Bangladesh: clinical findings, antibiotic susceptibility pattern and immune responses.","volume":"9","author":"Khanam","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"2025082815264171600_B59","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/00006454-200011000-00006","article-title":"Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children.","volume":"19","author":"Leibovitz","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"2025082815264171600_B60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/INF.0b013e31827ca763","article-title":"Estimates of illnesses, hospitalizations and deaths caused by major bacterial enteric pathogens in young children in the United States.","volume":"32","author":"Scallan","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"39","key":"2025082815264171600_B61","first-page":"1068","article-title":"Outbreaks of multidrug-resistant Shigella sonnei gastroenteritis associated with day care centers\u2014Kansas, Kentucky, and Missouri, 2005.","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2025082815264171600_B62","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijantimicag.2012.02.005","article-title":"Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from 1998 to 2009.","volume":"40","author":"Gu","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"2025082815264171600_B63","first-page":"318","article-title":"Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin\u2014United States, May 2014-February 2015.","volume":"64","author":"Bowen","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"2025082815264171600_B64","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.2105\/AJPH.2013.301867","article-title":"Epidemiology and antimicrobial resistance of international travel-associated Campylobacter infections in the United States, 2005-2011.","volume":"104","author":"Ricotta","year":"2014","journal-title":"Am J Public Health"},{"key":"2025082815264171600_B65","first-page":"1","article-title":"Treatment of tuberculosis.","volume":"52","author":"American Thoracic Society","year":"2003","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"2025082815264171600_B66","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0800106","article-title":"Comprehensive treatment of extensively drug-resistant tuberculosis.","volume":"359","author":"Mitnick","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"2025082815264171600_B67","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1473-3099(12)70033-6","article-title":"Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"12","author":"Ettehad","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2025082815264171600_B68","doi-asserted-by":"crossref","first-page":"624","DOI":"10.5588\/ijtld.12.0792","article-title":"Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009-2011.","volume":"17","author":"Gegia","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"2025082815264171600_B69","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tube.2015.02.037","article-title":"Fluoroquinolones for the treatment of tuberculosis in children.","volume":"95","author":"Thee","year":"2015","journal-title":"Tuberculosis (Edinb)"},{"issue":"11","key":"2025082815264171600_B70","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/cid\/civ156","article-title":"Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial.","volume":"60","author":"Torre-Cisneros","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025082815264171600_B71","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2014-0564","article-title":"Pediatric anthrax clinical management.","volume":"133","author":"Bradley","year":"2014","journal-title":"Pediatrics"},{"key":"2025082815264171600_B72","unstructured":"Centers for Disease Control and Prevention\n          . Plague. Available at: www.cdc.gov\/plague\/healthcare\/clinicians.html. Accessed July 6, 2015"},{"key":"2025082815264171600_B73","author":"Inglesby"},{"issue":"7","key":"2025082815264171600_B74","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/AAC.00064-11","article-title":"Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.","volume":"55","author":"Thwaites","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2025082815264171600_B75","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/INF.0b013e318245ab48","article-title":"Fluoroquinolones in children with fever and neutropenia: a systematic review of prospective trials.","volume":"31","author":"Sung","year":"2012","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-2706\/1356569\/peds_20162706.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-2706\/1356569\/peds_20162706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T19:26:55Z","timestamp":1756409215000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/138\/5\/e20162706\/60708\/The-Use-of-Systemic-and-Topical-Fluoroquinolones"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":75,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,11,1]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-2706","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,1]]},"article-number":"e20162706"}}